Open AccessRecurrent Vulvovaginal Candidiasis
Author(s) -
Cyntya Sari Sovianti,
Mutia Devi
Publication year - 2021
Publication title -
bioscientia medicina
Language(s) - English
Resource type - Journals
ISSN - 2598-0580
DOI - 10.32539/bsm.v5i3.280
Subject(s) - vulvovaginal candidiasis , candida albicans , asymptomatic , dermatology , sexually active , medicine , mycosis , invasive candidiasis , vaginal disease , biology , antifungal , immunology , vagina , fluconazole , microbiology and biotechnology , surgery , human immunodeficiency virus (hiv)
Vulvovaginal candidiasis is a common fungal infection caused by Candida Sp,especially Candida albicans. Recurrent vulvovaginal candidiasis was defined asthe occurrence of four or more episodes of vulvovaginal candidiasis in 12 monthsperiod. As many as 9% of women from various populations have recurrentvulvovaginal candidiasis. Vulvovaginal candidiasis affects the quality of life,mental health, and sexual activity. There are many predisposing factors thatcaused recurrent vulvovaginal candidiasis, such as genetics, host, habit,idiopathic and non-albican candida microbes. Management of recurrentvulvovaginal candidiasis includes elimination of predisposing factors; mycologicalculture diagnosis and identification of specific Candida species; followed bymicrobiological examination to confirm the sensitivity of the azole group toCandida sp. Further, oral, or topical therapy should be continued until the patientis asymptomatic and culture-negative. Patients should receive induction therapyfollowed by maintenance suppressive therapy for six months.